Pegasus Tech Ventures and CYBERDYNE Establish 10 Billion Yen Corporate Venture Capital Fund

Pegasus Tech Ventures and CYBERDYNE Inc. launched a 10 billion Japanese Yen corporate venture capital fund to accelerate the development of the Human Cybernics Production System (HCPS). According to the companies, the fund targets startups that integrate robotics, artificial intelligence, and human physiology to improve medical care and industrial productivity.

The partnership combines the global investment network of Pegasus Tech Ventures with the technical expertise of CYBERDYNE, a Japanese robotics firm known for its Hybrid Assistive Limb (HAL) exoskeleton. The fund is designed to identify and scale early-stage companies that align with the “cybernics” philosophy, which seeks to merge human biological signals with electronic systems.

What is the goal of the 10 billion yen fund?

The primary objective of the fund is to expand the ecosystem surrounding the Human Cybernics Production System, or HCPS. According to the announcement, this framework is not a single product but a comprehensive system for producing and implementing cybernic technologies across various sectors. The 10 billion yen commitment serves as a strategic vehicle to bring external innovation into CYBERDYNE’s technical orbit.

Investment targets include companies specializing in sensor technology, AI-driven movement analysis, and wearable robotics. By providing capital to these startups, the companies aim to reduce the time required to move cybernic concepts from the laboratory to commercial application. This approach shifts the burden of early-stage R&D from a single corporate entity to a broader network of agile startups.

How does the HCPS framework function?

The HCPS framework focuses on the science of cybernics, which CYBERDYNE defines as the integration of human biological systems with robotic technology. Unlike traditional industrial robotics that replace human labor, cybernics aims to augment or restore human capability. This is achieved by detecting bio-electrical signals from the skin’s surface and translating those signals into robotic motion.

The production system aspect of HCPS involves three core components:

• Biological Signal Processing: Capturing and interpreting the intent of the human user.
• Robotic Actuation: Providing the physical force necessary to assist movement or support a limb.
• Data Feedback Loops: Using AI to refine the interaction between the machine and the human body over time.

By investing in startups that improve any of these three areas, the fund seeks to enhance the precision and accessibility of exoskeleton technology and other assistive devices.

Why partner with Pegasus Tech Ventures?

CYBERDYNE is utilizing Pegasus Tech Ventures to gain access to a global pipeline of startups. While CYBERDYNE possesses the deep technical knowledge of robotics, Pegasus operates a global venture capital model that monitors thousands of startups across multiple continents. This partnership allows the fund to source technologies from the Americas, Europe, and Asia that might not be visible within the Japanese domestic market.

The structure of the fund differs from traditional venture capital. While standard VC firms prioritize rapid financial exits and high multiples, this corporate venture capital (CVC) model prioritizes strategic alignment. According to the partnership terms, the success of an investment is measured not only by financial return but by how much the technology advances the HCPS framework.

How does this differ from general robotics investment?

Most robotics funding currently focuses on automation, where machines operate independently of humans to increase efficiency in warehouses or factories. This fund takes a contrasting approach by focusing on “human-in-the-loop” systems. The goal is not to remove the human from the process but to enhance the human’s physical or cognitive ability.

This distinction is critical for Japan’s healthcare sector. With a rapidly aging population and a shrinking workforce, the Japanese government has prioritized technologies that allow elderly citizens to maintain mobility and caregivers to reduce physical strain. The HCPS-focused fund directly addresses these demographic pressures by investing in assistive rather than replacement technology.

The fund’s focus on cybernics creates a narrower, more specialized investment mandate than general AI or robotics funds. It requires startups to demonstrate a specific capability in biological integration, making the barrier to entry higher but the strategic value to CYBERDYNE more significant.